针对阿尔茨海默病的BACE抑制剂临床试验
Elyse A Watkins1, Robert Vassar1,2
1Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Journal of Alzheimer's disease : JAD
|October 18, 2024
概括
BACE1 抑制剂通过减少粉样β 斑块,对阿尔茨海默病有很大的前景. 然而,高抑制水平导致认知能力下降,需要研究更低,更安全的剂量,以有效治疗阿尔茨海默病.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 粉样蛋白假说表明,粉样蛋白-β聚合物导致阿尔茨海默病.
- 抗粉样β抗体试验表明,斑块清除可以改善认知能力.
- BACE1 抑制剂提供了一种口服的,具有成本效益的方法来减少粉样β的产生.
研究的目的:
- 为了研究BACE1抑制剂在阿尔茨海默病中的认知副作用.
- 为了确定较低的BACE1抑制水平是否可以减缓阿尔茨海默氏症的病理,同时避免认知能力下降.
- 探索BACE1抑制剂作为阿尔茨海默病预防或维持疗法的潜力.
主要方法:
- 对BACE1抑制剂的临床试验数据的审查.
- 关于BACE1抑制值的遗传证据分析.
- 研究BACE1的其他基质及其在认知功能中的作用.
主要成果:
- BACE1抑制剂有效降低了粉样β的产生.
- 高水平的BACE1抑制 (>50%) 与可逆性认知衰退有关.
- 遗传研究表明,30%的BACE1抑制可能足以保护阿尔茨海默氏症.
结论:
- BACE1抑制剂有可能用于阿尔茨海默病的治疗,但需要剂量优化以减轻认知副作用.
- 降低BACE1抑制水平可能为减缓阿尔茨海默病进展而没有不良认知影响提供治疗窗口.
- 优化的BACE1抑制剂可以作为阿尔茨海默病的首要预防或维持疗法.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
1.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
101
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
101
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K